PHARVARIS NV

Pharvaris insider sales show routine liquidity moves, not loss of confidence—evaluate the clinical‑stage B2 antagonist pipeline for long‑term upside.

Pharvaris NV insider trades reveal a strategic mix of buying at €8.05, selling at €29.32 and holding 25,167 shares—showing confidence in β2‑antagonist breakthroughs and market momentum.

Pharvaris NV insider trading reveals CEO liquidity moves—yet the firm’s strong B2 antagonist pipeline and outcome‑based pricing strategy keep long‑term prospects bright.

Pharvaris NV insiders buy at discount, sell at premium and liquidate options—showing bullish confidence in its B₂‑receptor pain drugs and upcoming regulatory approvals.

Pharvaris insider sale sparks debate: learn how a routine 109‑share sell reflects confidence amid strong rally, regulatory milestones, and extended‑release innovation.

Pharvaris insider sales show routine liquidity moves, not a sign of confidence, as the stock keeps rising on solid earnings and a strong B2‑receptor pipeline.

Pharvaris insider trades show confidence in its oral B2 antagonist pipeline for fibrosis, with Lu Peng buying low, selling high, and signaling a steady upside.

Pharvaris NV insider sales show routine, Rule 10b‑5‑1‑guided moves—no bearish signal, just confident execs backing a promising B2‑receptor pain drug amid rising investor interest.

Pharvaris insider sales signal a strategic re‑balance: Nijdam Anna cuts stake while keeping 49,488 shares, hinting at liquidity optimisation amid clinical‑stage growth.

Pharvaris NV insider sale: Anna Nijdam sold 1,164 shares at $28.25 on Apr 1, 2026. The modest move signals liquidity, not a bearish stance, amid key Phase‑3 and NDA milestones that could drive future upside.